Clinical Trial
Trial Status Change: Phase 3 Finerenone Study in Pediatric Heart Failure Now Recruiting
Signal observed that a Phase 3 trial evaluating finerenone safety in pediatric heart failure patients with left ventricular systolic dysfunction has transitioned from planning to active recruitment. The single-arm, open-label extension study encompasses patients from birth to 18 years of age, representing a significant development in pediatric heart failure therapeutics. Worth noting this represents one of the few Phase 3 trials specifically designed for pediatric heart failure across such a broad age range.
Relevance: Directly relevant to practice interest in pediatric heart failure and aligns with formulary focus on heart failure medications, though finerenone represents a newer therapeutic class not yet in the current formulary.
NCT07192952